摘要
肝细胞癌是临床中最常见的恶性肿瘤之一。由于早期缺乏典型的临床表现,我国大多数患者确诊时已达中晚期,错失手术切除机会,预后较差。因此通过相关治疗手段将不可切除肝细胞癌转化为可切除肝细胞癌的探索十分必要。近年来,随着经动脉介入治疗、放射治疗技术等局部治疗的不断进步完善、新的靶向及免疫药物的临床应用,为肝细胞癌的转化治疗模式带来了新的机遇和挑战,而局部治疗联合系统治疗产生更好联合治疗作用,提高手术转化率。本文旨在对目前局部联合系统治疗在肝细胞癌转化治疗中的价值,为不可切除肝细胞癌的临床治疗提供参考。
Hepatocellular carcinoma(HCC)is one of the most common malignant tumors in clinical practice.Due to the lack of typical clinical manifestations in the early stage,most patients in China are in the advanced stage at the time of confirmed diagnosis and thus lose the opportunity for surgical resection,which leads to a poor prognosis.Therefore,it is necessary to explore related therapies for converting unresectable HCC into resectable HCC.In recent years,the improvement in local therapy such as transarterial interventional therapies and radiation therapy technology,together with the clinical application of new targeted therapies and immune checkpoint inhibitors,has brought new opportunities and challenges in the conversion therapy for advanced HCC,and local therapy combined with systemic therapy may have a good synergistic effect,improve the conversion rate of surgery.This article investigates the value of local therapy combined with systemic therapy in the conversion therapy for HCC,in order to provide a basis for the clinical treatment of unresectable HCC.
作者
朱超凡
王晓东
ZHU Chaofan;WANG Xiaodong(Key Laboratory of Pathogenesis and Transformation of Malignant Tumors,Ministry of Education,Department of Interventional Therapy,Peking University Cancer Hospital&Institute,Beijing 100142,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2024年第9期1732-1737,共6页
Journal of Clinical Hepatology
基金
国家自然科学基金面上项目(82172039)
北京市医院管理中心临床医学发展专项经费资助(ZYLX202117)
北京市自然科学基金面上项目(7212198)。
关键词
癌
肝细胞
转化治疗
介入治疗
系统治疗
联合治疗
Carcinoma,Hepatocellular
Conversion Therapy
Interventional therapy
Systemic therapy
Combination Therapy
